Ropinirole for the Treatment of Hyperprolactinemia: A Dose-Escalation Study of Efficacy and Tolerability
The Journal of Clinical Endocrinology & Metabolism · 2024
DOI: 10.1210/clinem/dgad545 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von Liam J Heneghan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Columbia University, Vagelos College of P&S, New York, NY 10032, USA. Hauptthemen laut MEDLINE: Hyperprolactinemia, Pituitary Neoplasms, Prolactinoma, Galactorrhea. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NCRR NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
Context
Treatment of hyperprolactinemia with ergoline dopamine agonists (DAs) can be complicated by intolerance and resistance.
Objective
This study examines the efficacy and tolerability of the nonergot DA ropinirole for the long-term treatment of hyperprolactinemia.
Methods
Twelve hyperprolactinemic women were treated with ropinirole in a 6-month, open-label, dose-escalation trial; 7 of the 12 continued treatment in an extension study for up to 17 months. Ropinirole doses were uptitrated to achieve normal prolactin (PRL) levels, restore menses, and eliminate galactorrhea.
Results
Two of the 12 participants were DA naive; 6 of 12 were ergot DA intolerant; and 1 of 12 had known ergot DA resistance. Baseline PRL levels were 126.2 ± 41.4 ng/mL (SEM). Ropinirole was uptitrated from 0.125 to 0.25 mg/h to a median total daily dose (TDD) of 2 mg/d (1-4 mg/d [interquartile range]). PRL normalization was achieved in 50% of the participants (5 with microadenomas and 1 with idiopathic hyperprolactinemia) at a median effective TDD of 1 mg/d. Of the patients achieving PRL normalization, 83% were ergot DA intolerant. A persistent partial biochemical response (PRL reduction >50% from baseline) was achieved in 17% of the participants. During treatment, menses resumed in 67% of amenorrheic patients; galactorrhea resolved in 67%. Mild adverse effects were reported in 92% of participants; however, ropinirole was not discontinued because of intolerance even among the 50% of individuals with a prior history of ergot DA intolerance and resultant medication discontinuation.
Conclusion
These data demonstrate the efficacy and tolerability of ropinirole for the treatment of hyperprolactinemia in patients with microprolactinomas and idiopathic hyperprolactinemia and suggest ropinirole may represent a novel therapeutic alternative for treating hyperprolactinemic disorders in patients with ergot DA intolerance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Columbia University, Vagelos College of P&S, New York, NY 10032, USA.
- Department of Radiology, Columbia University Irving Medical Center, New York, NY 10032, USA.
ORCID-Profile: Gabrielle Page-Wilson
Förderung
- NIDDK NIH HHS
- NCRR NIH HHS
- NCATS NIH HHS
- NIH HHS
- National Center for Advancing Translational Sciences
- National Institutes of Health
- Irving Institute for Clinical and Translational Research/Clinical Trials Office Pilot Award
Zitieren
APA
Heneghan, L. J., Tsang, A., Dimino, C., Khandji, A. G., Panigrahi, S. K., & Page-Wilson, G. (2024). Ropinirole for the Treatment of Hyperprolactinemia: A Dose-Escalation Study of Efficacy and Tolerability. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad545
Vancouver
Heneghan LJ, Tsang A, Dimino C, Khandji AG, Panigrahi SK, Page-Wilson G. Ropinirole for the Treatment of Hyperprolactinemia: A Dose-Escalation Study of Efficacy and Tolerability. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgad545
BibTeX
@article{Heneghan2024,
author = {Heneghan, Liam J and Tsang, Amanda and Dimino, Cara and Khandji, Alexander G and Panigrahi, Sunil K and Page-Wilson, Gabrielle},
title = {Ropinirole for the Treatment of Hyperprolactinemia: A Dose-Escalation Study of Efficacy and Tolerability},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2024},
doi = {10.1210/clinem/dgad545}
}
EUVIMED